The company utilizes drug-inducing factors that regulate the intracellular AKT pathway to develop therapies for infertile women who do not benefit from standard hormone therapy. By focusing on the early and hormone-independent phase of egg maturation, Notify Therapeutics aims to provide a unique solution to infertility that has not been addressed by current treatments.